José A Arranz, Cristina Martínez, Lucía Gallego, Ana Heredero, Pablo Rebollo, Laura Fernández, Elvira Estella, David Vilanova Larena, Virginia Palomar
{"title":"西班牙RCC一线及后续治疗模式。一个真实世界的描述性横断面研究。","authors":"José A Arranz, Cristina Martínez, Lucía Gallego, Ana Heredero, Pablo Rebollo, Laura Fernández, Elvira Estella, David Vilanova Larena, Virginia Palomar","doi":"10.1080/14796694.2025.2542030","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Advanced renal cell carcinoma (RCC) has had limited treatment options and poor prognosis. Initially, tyrosine kinase inhibitors (TKIs) increased progression-free survival (PFS) and allowed the identification of favorable (FP), intermediate (IP) and poor prognosis (PP) subgroups. While TKIs remain an option for FP patients, combinations of immune checkpoint inhibitors (IO) plus TKI in the overall population, or IO/IO in IP/PP patients, have improved overall survival (OS), and have become the standard of care. However, their adoption in clinical practice varies across countries.</p><p><strong>Method: </strong>We conducted a cross-sectional observational study using Oncology Dynamics™ database to assess treatment patterns in Spain.</p><p><strong>Results: </strong>A total of 1,587 metastatic RCC (mRCC) patients were registered, 900 in first-line treatment for clear cell mRCC (mccRCC). In 2022, among mccRCC FP patients treated by oncologists (N = 137), 92.7% received TKIs; while IP/PP patients (N = 298), 56.7% received TKIs, 27.5% antiPD1-antiCTLA4, and 13.8% antiPD1-TKI. In 2023, mccRCC FP patients (N = 124) received 94.4% TKIs; and IP/PP patients (N = 256) received 48.4% TKIs, 38.3% antiPD1-antiCTLA4, and 12.1% antiPD1-TKI.</p><p><strong>Conclusions: </strong>During this period, the uptake of IO/IO and IO/TKI in clinical practice in Spain was lower than expected according to current recommendations.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2767-2774"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407652/pdf/","citationCount":"0","resultStr":"{\"title\":\"Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study.\",\"authors\":\"José A Arranz, Cristina Martínez, Lucía Gallego, Ana Heredero, Pablo Rebollo, Laura Fernández, Elvira Estella, David Vilanova Larena, Virginia Palomar\",\"doi\":\"10.1080/14796694.2025.2542030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Advanced renal cell carcinoma (RCC) has had limited treatment options and poor prognosis. Initially, tyrosine kinase inhibitors (TKIs) increased progression-free survival (PFS) and allowed the identification of favorable (FP), intermediate (IP) and poor prognosis (PP) subgroups. While TKIs remain an option for FP patients, combinations of immune checkpoint inhibitors (IO) plus TKI in the overall population, or IO/IO in IP/PP patients, have improved overall survival (OS), and have become the standard of care. However, their adoption in clinical practice varies across countries.</p><p><strong>Method: </strong>We conducted a cross-sectional observational study using Oncology Dynamics™ database to assess treatment patterns in Spain.</p><p><strong>Results: </strong>A total of 1,587 metastatic RCC (mRCC) patients were registered, 900 in first-line treatment for clear cell mRCC (mccRCC). In 2022, among mccRCC FP patients treated by oncologists (N = 137), 92.7% received TKIs; while IP/PP patients (N = 298), 56.7% received TKIs, 27.5% antiPD1-antiCTLA4, and 13.8% antiPD1-TKI. In 2023, mccRCC FP patients (N = 124) received 94.4% TKIs; and IP/PP patients (N = 256) received 48.4% TKIs, 38.3% antiPD1-antiCTLA4, and 12.1% antiPD1-TKI.</p><p><strong>Conclusions: </strong>During this period, the uptake of IO/IO and IO/TKI in clinical practice in Spain was lower than expected according to current recommendations.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"2767-2774\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407652/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2542030\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2542030","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study.
Aim: Advanced renal cell carcinoma (RCC) has had limited treatment options and poor prognosis. Initially, tyrosine kinase inhibitors (TKIs) increased progression-free survival (PFS) and allowed the identification of favorable (FP), intermediate (IP) and poor prognosis (PP) subgroups. While TKIs remain an option for FP patients, combinations of immune checkpoint inhibitors (IO) plus TKI in the overall population, or IO/IO in IP/PP patients, have improved overall survival (OS), and have become the standard of care. However, their adoption in clinical practice varies across countries.
Method: We conducted a cross-sectional observational study using Oncology Dynamics™ database to assess treatment patterns in Spain.
Results: A total of 1,587 metastatic RCC (mRCC) patients were registered, 900 in first-line treatment for clear cell mRCC (mccRCC). In 2022, among mccRCC FP patients treated by oncologists (N = 137), 92.7% received TKIs; while IP/PP patients (N = 298), 56.7% received TKIs, 27.5% antiPD1-antiCTLA4, and 13.8% antiPD1-TKI. In 2023, mccRCC FP patients (N = 124) received 94.4% TKIs; and IP/PP patients (N = 256) received 48.4% TKIs, 38.3% antiPD1-antiCTLA4, and 12.1% antiPD1-TKI.
Conclusions: During this period, the uptake of IO/IO and IO/TKI in clinical practice in Spain was lower than expected according to current recommendations.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
